Dong-A ST, AbbVie deal

Dong-A granted AbbVie exclusive, worldwide rights, excluding South Korea, to an undisclosed c-Mer proto-oncogene tyrosine kinase (MERTK) inhibitor, which is in preclinical development to treat cancer....